Table 5.
Summary of studies on NLR and/or PLR in NSCLC
| Study | Country | No. of patients | Cut-off value | Details of patients | |
|---|---|---|---|---|---|
| NLR | PLR | ||||
| Sarraf, 2009 | UK | 177 | † | ‡ | Ia-IV, 33% stage Ib¶; 59% male; 49% AC§; all underwent surgical resection |
| Teramukai, 2009 | Japan | 388 | 2.093, 2.914 and 4.744 | ‡ | IIIb-IV, 82% stage IV¶; 71% male; 70% AC§; all received chemotherapy |
| Sakai, 2011 | Japan | 23 | † | ‡ | Ia-IIIb, 60.9% stage Ib¶; 60.9% male; 100% AC§; all underwent surgical resection |
| Tomita, 2012£ | Japan | 284 | 2.5 | ‡ | I-III, 63.5% stage I; 63.5% male; 72.8% AC§; all underwent surgical resection |
| Forget, 2013 | Belgium | 255 | 5.0 | ‡ | I-II, 76% stage I¶; 82.4% male; 53.3% AC§; all underwent surgical resection |
| Unal, 2013 | Turkey | 94 | 3.44 | 194 | II-IIIb, 47.9% stage IIIb¶; 93.6% male; 70.2% SCC§; all received chemotherapy, partial received radiotherapy |
| Kacan | Turkey | 270 | 5.0 | ‡ | I-IV, 66.7% stage III¶, 90% male; 41% SCC§; therapy strategy was not stated |
| Cedres, 2012 | Spain | 171 | 5.0 | ‡ | 100% stage IV¶; 83% male; 40.5% AC§; all patients received first-line chemotherapy |
| Lee, 2012 | Korea | 199 | 3.25 | ‡ | III b-IV, 92% stage IV¶; 8.5% male; 100% AC§; all patients received first-line chemotherapy; never smokers |
| Jafri, 2013 | USA | 173 | 5.0 | ‡ | 100% stage IV¶; 67% male; 52% AC§; 66% received chemotherapy |
| Kaya, 2013 | Turkey | 156 | 5 | 150 | IIIa-IV, 40.4% stage IIIa¶; 51.3% male; 54.8% SCC§; 66% received chemotherapy |
| Yao, 2012 | China | 182 | 2.63 | ‡ | III-IV, 68.1 % stage IV¶; 65.4 % male; 70.3 % AC§; all patients received first-line chemotherapy |
| Liu, 2013 | China | 210 | ‡ | 152.6 | III-IV, 70.5 % stage IV¶; 66.2 % male; 66.2 % AC§; all patients received first-line chemotherapy |
| Sanchez-Lara, 2012 | Mexico | 119 | 5.0 | 150 | IIIb-IV, 72.3 % IIIb; 46.2 % male; No histology information; all patients received first-line chemotherapy |
| Pinato, 2014 | UK | 220 | 5.0 | 300 | Ia-IIIa, 34 % Ia; 50 % male; 60 % AC§; all underwent surgical resection |
†It was investigated but not offered; ‡It was not investigated in this study; §The largest portion of histological sub-type was presented; ¶The largest portion of non-small cell lung cancer (NSCLC) stage was presented; £This author conducted two studies in this field and the latter with more patients was chosen. AC, adenocarcinoma; NLR, neutrophil to lymphocyte ratio; PLR, platelet to lymphocyte ratio; SCC, squamous carcinoma.